BR112016004911A2 - Proteína secretada, acídica e rica em cisteína, um novo alvo para o tratamento e prevenção de insuficiência aguda do fígado - Google Patents
Proteína secretada, acídica e rica em cisteína, um novo alvo para o tratamento e prevenção de insuficiência aguda do fígadoInfo
- Publication number
- BR112016004911A2 BR112016004911A2 BR112016004911A BR112016004911A BR112016004911A2 BR 112016004911 A2 BR112016004911 A2 BR 112016004911A2 BR 112016004911 A BR112016004911 A BR 112016004911A BR 112016004911 A BR112016004911 A BR 112016004911A BR 112016004911 A2 BR112016004911 A2 BR 112016004911A2
- Authority
- BR
- Brazil
- Prior art keywords
- acute liver
- liver failure
- secreted
- cysteine
- acidic
- Prior art date
Links
- 208000007788 Acute Liver Failure Diseases 0.000 title abstract 3
- 206010000804 Acute hepatic failure Diseases 0.000 title abstract 3
- 231100000836 acute liver failure Toxicity 0.000 title abstract 3
- 101000881168 Homo sapiens SPARC Proteins 0.000 title abstract 2
- 101000621511 Potato virus M (strain German) RNA silencing suppressor Proteins 0.000 title abstract 2
- 102100037599 SPARC Human genes 0.000 title abstract 2
- 230000002378 acidificating effect Effects 0.000 title abstract 2
- 101800000263 Acidic protein Proteins 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 206010019772 Hepatitis fulminant Diseases 0.000 abstract 1
- 206010067125 Liver injury Diseases 0.000 abstract 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 231100000439 acute liver injury Toxicity 0.000 abstract 1
- 230000008827 biological function Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
MÉTODO PARA PREVENIR OU TRATAR INSUFICIÊNCIA HEPÁTICA AGUDA OU LESÃO HEPÁTICA AGUDA, COMPOSIÇÃO FARMACÊUTICA, USO DE UM AGENTE, AGENTE, CONSTRUTO GENÉTICO E SIRNA. A invenção refere-se à identificação de Proteína Secretada, Acídica e Rica em Cisteína (SPARC) como um novo alvo terapêutico em pacientes com hepatite fulminante permitindo o desenvolvimento de uma estratégia destinada a proteger o fígado de lesão. A invenção concerne o tratamento de insuficiência hepática aguda ou hepatite fulminante por administração a um paciente dele necessitado de um agente que inibe ao menos parcialmente a expressão de SPARC e/ou interfere com sua função biológica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361874191P | 2013-09-05 | 2013-09-05 | |
PCT/IB2014/064295 WO2015033309A2 (en) | 2013-09-05 | 2014-09-05 | Sparc (secreted protein, acidic and rich in cysteine), a new target for the treatment and prevention of acute liver failure |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016004911A2 true BR112016004911A2 (pt) | 2017-09-05 |
Family
ID=51842697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016004911A BR112016004911A2 (pt) | 2013-09-05 | 2014-09-05 | Proteína secretada, acídica e rica em cisteína, um novo alvo para o tratamento e prevenção de insuficiência aguda do fígado |
Country Status (5)
Country | Link |
---|---|
US (1) | US10385114B2 (pt) |
EP (1) | EP3041861B1 (pt) |
AR (1) | AR099641A1 (pt) |
BR (1) | BR112016004911A2 (pt) |
WO (1) | WO2015033309A2 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113041262B (zh) * | 2019-12-26 | 2023-08-04 | 中国科学院分子细胞科学卓越创新中心 | 内胚层干细胞在预防和/或治疗肝脏免疫失调疾病中的应用 |
WO2024095178A1 (en) | 2022-11-01 | 2024-05-10 | Janssen Pharmaceutica Nv | Thrombopoietin mimetic for use in the treatment of acute liver failure |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2284266B1 (en) * | 2002-11-14 | 2013-11-06 | Thermo Fisher Scientific Biosciences Inc. | siRNA targeting tp53 |
JP2011516609A (ja) | 2008-04-14 | 2011-05-26 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Sparc抗炎症活性及びその使用 |
BRPI0909866B1 (pt) | 2008-06-11 | 2021-08-24 | Fresenius Medical Care Deutschland Gmbh | Método de produção de um meio condicionado de células progenitoras de fígado, meio condicionado e composição farmacêutica |
-
2014
- 2014-09-05 AR ARP140103325A patent/AR099641A1/es not_active Application Discontinuation
- 2014-09-05 BR BR112016004911A patent/BR112016004911A2/pt not_active Application Discontinuation
- 2014-09-05 US US14/916,948 patent/US10385114B2/en active Active
- 2014-09-05 WO PCT/IB2014/064295 patent/WO2015033309A2/en active Application Filing
- 2014-09-05 EP EP14790721.6A patent/EP3041861B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20160201057A1 (en) | 2016-07-14 |
WO2015033309A2 (en) | 2015-03-12 |
AR099641A1 (es) | 2016-08-10 |
EP3041861A2 (en) | 2016-07-13 |
US10385114B2 (en) | 2019-08-20 |
WO2015033309A3 (en) | 2015-11-12 |
EP3041861B1 (en) | 2019-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019000268A1 (es) | Composición de cannabis. | |
BR112018075960A2 (pt) | moléculas de ácido nucleico para a redução de mrna de papd5 ou papd7 para o tratamento de infecção pela hepatite b | |
BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
BR112017003546A2 (pt) | amidas heterocíclicas como inibidores de rip1 quinase como medicamentos | |
BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
BR112018003898A2 (pt) | material auxiliar para aplicação no tecido de cólon | |
AR105712A1 (es) | Composiciones de insulina de rápida acción | |
BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
BR112017028132A2 (pt) | métodos de tratamento de malignidade hematológica usando terapia combinada de inibidor de mtor em nanopartícula | |
BR112015006623A2 (pt) | laquinimod e pridopidina para o tratamento de doenças neurodegenerativas | |
CR20120638A (es) | Métodos de terapia combinada para tratar enfermedades proliferativas | |
BR112015009948A8 (pt) | Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios | |
BR112014011896A2 (pt) | agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr) | |
BR112014016672A2 (pt) | compostos de carbamato e sua preparação e uso | |
BR112013018920A2 (pt) | composições de nanopartículas, formulações destas e seus usos | |
BR112015022650A2 (pt) | inibidores de cinase induzível por sal macrocíclico | |
UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
BR112017020948A2 (pt) | composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão | |
BR112017014361A2 (pt) | métodos para aperfeiçoamento de terapia celular | |
BR112014019399A2 (pt) | métodos de tratamento da fibrose | |
BR112016028446A2 (pt) | inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5 | |
BR112015030355A2 (pt) | método para tratar, melhorar, inverter, proteger ou prevenir um indivíduo ou um paciente contra uma patologia, uma cardiopatia ou uma doença cardiovascular, uso, e, formulação terapêutica | |
BR112015022982A2 (pt) | inibidores macrocíclicos de rip2 quinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |